Breaking News

ImmunoGen, Takeda Partner to Commercialize ELAHERE in Japan

ImmunoGen retains production rights and will supply product for development and commercial use in Japan.

ImmunoGen, Inc., a company involved in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, has entered into an exclusive collaboration with Takeda Pharmaceutical Co. to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen will receive a one-time, upfront payment and an additional payment upon conversion of U.S. FDA accelerated approval of ELAHERE in platinum-resistant ovarian cancer (PROC) to full approval. The company is eligi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters